Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

Summary

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

Timeline

Start

2025-12-03

Primary completion

2026-12-03

Completion

2027-12-03

Drugs

Indications